Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clozapine
Drug ID BADD_D00511
Description A tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.
Indications and Usage For use in patients with treatment-resistant schizophrenia.
Marketing Status Prescription; Discontinued
ATC Code N05AH02
DrugBank ID DB00363
KEGG ID D00283
MeSH ID D003024
PubChem ID 135398737
TTD Drug ID D0Z1RV
NDC Product Code 57664-345; 0904-7088; 16729-141; 71554-025; 0093-3086; 51079-921; 55154-3568; 60687-404; 0378-3815; 51407-086; 0093-3087; 52817-601; 76072-1010; 0378-0972; 60687-548; 51862-274; 60429-989; 64374-004; 70518-3391; 12828-0072; 0378-0825; 60687-415; 53296-0033; 65862-846; 57664-241; 55154-8285; 57664-347; 65015-706; 60429-990; 51862-901; 0378-3813; 51407-085; 63552-062; 63629-2360; 69809-0126; 60687-426; 63629-2361; 72721-1725; 72721-1760; 0093-4404; 0904-7089; 67835-0028; 65862-847; 16729-142; 0378-0860; 57664-211; 51862-903; 0093-7772; 51862-273; 65862-844; 51079-749; 51079-922; 0093-5377; 0904-7087; 63629-2362; 65862-845; 70518-3357; 63552-063; 0093-5416; 69809-0130; 72721-1750; 51079-288; 72721-1770; 0093-4359; 0093-5419; 69809-0127; 0093-5376; 69809-0135; 63629-2359; 0378-0973; 73377-150; 51862-902; 0093-5417; 0093-4405; 51862-900
Synonyms Clozapine | Clozaril | Leponex
Chemical Information
Molecular Formula C18H19ClN4
CAS Registry Number 5786-21-0
SMILES CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Tardive dyskinesiaD(4) dopamine receptorP21917T2498310821369; 10379516; 10893495; 9777180; 10889553
Tardive dyskinesiaD(2) dopamine receptorP14416T6716210821369; 10379516; 10893495; 9777180; 10889553
Tardive dyskinesiaD(3) dopamine receptorP35462T0255110821369; 10379516; 10893495; 9777180; 10889553
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Communication disorder19.19.01.0080.016814%Not Available
Disturbance in social behaviour19.05.01.0180.033629%Not Available
Escherichia infection11.02.10.0040.014012%Not Available
Heart injury12.01.11.003; 02.01.01.010--Not Available
Investigation abnormal13.18.01.0020.008407%Not Available
Neutrophil count abnormal13.01.06.0180.028024%Not Available
Psychotic disorder due to a general medical condition19.03.01.0080.005605%Not Available
Platelet aggregation13.01.04.0030.011210%Not Available
Rectal neoplasm16.13.02.002; 07.21.10.0020.001462%Not Available
Spinal cord neoplasm17.20.01.009; 16.30.01.0090.005605%Not Available
Antipsychotic drug level increased13.17.01.0300.650157%Not Available
Accidental death12.01.08.040; 08.04.01.0130.003655%Not Available
Atrioventricular septal defect03.07.02.005; 02.04.02.0290.005605%Not Available
Conduct disorder19.21.04.0020.005605%Not Available
Faecal vomiting07.01.07.0130.005605%Not Available
Tachyphrenia19.10.03.010; 17.03.03.0070.008407%Not Available
Post procedural myocardial infarction12.02.01.009; 02.02.02.0180.001462%Not Available
Post procedural sepsis12.02.05.049; 11.01.11.0130.001462%Not Available
Stomach mass07.11.01.0300.005605%Not Available
Vitello-intestinal duct remnant07.11.04.012; 03.04.04.0070.005605%Not Available
Procalcitonin increased13.09.01.0260.011210%Not Available
Carotid arteriosclerosis24.04.06.031; 17.08.02.0150.005605%Not Available
Right atrial dilatation02.04.02.0320.022419%Not Available
Left atrial dilatation02.04.02.0250.047641%Not Available
Apparent death08.01.03.0620.008407%Not Available
Quality of life decreased13.18.01.013--Not Available
Tobacco interaction08.06.03.0070.008407%Not Available
Schizoaffective disorder bipolar type19.03.02.0030.014012%Not Available
Respiratory tract inflammation22.02.07.0150.005605%Not Available
Frontotemporal dementia17.03.01.007; 19.20.02.0080.005605%Not Available
The 47th Page    First    Pre   47 48    Next   Last    Total 48 Pages